Investor Presentaiton

Investor presentation Full year 2018 Slide 55 Novo Nordisk is the market leader in the USA within the modern and new-generation insulin segment USA insulin market by segment Device penetration - Novo Nordisk Modern insulin and new-generation insulin volume market shares in the USA Sanofi Eli Lilly Modern insulin penetration tMU Penetration CAGR volume¹: 2.1% 160 100% 60% CAGR value¹: 17.1% 140 50% 80% 120 Fast-acting 40% 100 60% 80 Premix 30% 60 40% 20% 40 Long-acting 20% 10% 20 0 0% 0% Nov 2013 Nov 2018 Nov 2013 1 CAGR for 5-year period Source: IQVIA monthly MAT Nov, 2018 volume and value figures changing diabetes Note: Data is sensitive to changes in IQVIA data collection and reporting methodology, does not add up to 100% as only selected pharmaceutical companies are included Source: IQVIA monthly MAT Nov, 2018 volume figures 41% 31% 27% Nov 2018 novo nordisk

View entire presentation